Drugs & Pharmaceuticals

The controversy surrounding ivermectin as a therapy for COVID has been longstanding and fierce. A recent paper in NEJM may or may not settle the ongoing debate. But the paper is full of data. Here is a condensed look at the key numbers.
Antibiotic R&D is hard. Getting to approval is harder. Surviving the commercialization step today is almost impossible. Government-based funding to fix the broken antibiotic market is essential to stop this march of the lemmings. Private investment will follow a government incentive and amplify its effect.
Two months ago, there was a mad rush to get the two oral antiviral pills approved to treat COVID-19. Pharmacies often ran out of these drugs within hours of delivery. Now, no one wants them. What is going on?
Sports fans will never forget the day in 1991 when L.A. Lakers star Earvin "Magic" Johnson announced that he was infected with HIV. Johnson was lucky; he survived long enough to see the advent of the first effective AIDS drugs. But not everyone was so lucky.
Should the COVID drug Paxlovid be available without a prescription? Some argue that pharmacists should be able to distribute the drug to people who have tested positive for COVID while others, including the AMA, believe that only physicians should be able to prescribe the drug because of some potentially dangerous drug-drug interactions. Cato Institute's Dr. Jeffrey Singer weighs in.
The Biden administration announced a "test to treat" plan to provide easy access to Paxlovid – an effective COVID antiviral drug – for anyone who's infected. It's not perfect, but it's sorely needed.
Have you ever tasted a medicine pill that’s so bitter that you can barely swallow it? Most adults can handle it. But with kids, bitterness can affect compliance. Here’s some clever chemistry to the rescue.
The Olympics (mercifully) is over. There were four doping incidents, one of which was a doozy. So this is a fine time to discuss a lesser-known class of drugs called SARMs? These drugs are not anabolic steroids, but they act very much like them. (Bodybuilders love them, too.)
In the mood for a lesson on drug-drug interactions? I didn't think so. But you got one anyhow. Might as well read it, no?
Pull incentives to fix the broken antibiotic marketplace – like a subscription payment of several billion dollars per needed antibiotic – are finally going to be implemented in 2032. What happens then? But before we get there … a brief word about blogging on Google’s Blogger.
An unexpected delay in the FDA's authorization of COVID shots for children under age 5 could amplify parents' existing concerns about vaccinating their kids. Here's what we know about the situation.
From the very beginning, the FDA knew that the COVID-19 vaccine was linked to serious heart trouble in recipients. The FDA medical officer review [1] of Pfizer’s original COVID-19 application notes “clinically important serious adverse reactions [included] anaphylaxis and myocarditis/pericarditis.” There is an urgent need for the FDA, CDC, and manufacturers to thoroughly investigate serious heart-related adverse events after the Pfizer and Moderna COVID vaccines.